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Abstract Progression through the mitotic cell cycle requires periodic regulation of gene function
at the levels of transcription, translation, protein-protein interactions, post-translational
modification and degradation. However, the role of alternative splicing (AS) in the temporal control
of cell cycle is not well understood. By sequencing the human transcriptome through two
continuous cell cycles, we identify ~ 1300 genes with cell cycle-dependent AS changes. These
genes are significantly enriched in functions linked to cell cycle control, yet they do not significantly
overlap genes subject to periodic changes in steady-state transcript levels. Many of the periodically
spliced genes are controlled by the SR protein kinase CLK1, whose level undergoes cell cycle-
dependent fluctuations via an auto-inhibitory circuit. Disruption of CLK1 causes pleiotropic cell
cycle defects and loss of proliferation, whereas CLK1 over-expression is associated with various
cancers. These results thus reveal a large program of CLK1-regulated periodic AS intimately
associated with cell cycle control.
DOI: 10.7554/eLife.10288.001
Introduction
Alternative splicing (AS) is a critical step of gene regulation that greatly expands proteomic diversity.
Nearly all (>90%) human genes undergo AS and a substantial fraction of the resulting isoforms are
thought to have distinct functions (Pan et al., 2008; Wang et al., 2008). AS is tightly controlled, and
its mis-regulation is a common cause of human diseases (Wang and Cooper, 2007). Generally, AS is
regulated by cis-acting splicing regulatory elements that recruit trans-acting splicing factors to pro-
mote or inhibit splicing (Matera and Wang, 2014; Wang and Burge, 2008). Alterations in splicing
factor expression have been observed in many cancers and are thought to activate cancer-specific
splicing programs that control cell cycle progression, cellular proliferation and migration (David and
Manley, 2010; Oltean and Bates, 2014). Consistent with these findings, several splicing factors
function as oncogenes or tumor suppressors (Karni et al., 2007; Wang et al., 2014), and cancer-
specific splicing alterations often affect genes that function in cell cycle control (Tsai et al., 2015).
Progression through the mitotic cell cycle requires periodic regulation of gene function that is pri-
marily achieved through coordination of protein levels with specific cell cycle stages
(Harashima et al., 2013; Vermeulen et al., 2003). This temporal coordination enables timely control
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of molecular events that ensure accurate chromatin duplication and daughter cell segregation. Peri-
odic gene function is conventionally thought to be achieved through stage-dependent gene tran-
scription (Bertoli et al., 2013), translation (Grabek et al., 2015), protein-protein interactions
(Satyanarayana and Kaldis, 2009), post-translational protein modifications, and ubiquitin-depen-
dent protein degradation (Mocciaro and Rape, 2012). Although AS is one of the most widespread
mechanisms involved in gene regulation, the relationship between the global coordination of AS and
the cell cycle has not been investigated.
Major families of splicing factors include the Serine-Arginine rich proteins (SR) proteins and the
heterogeneous nuclear ribonucleoproteins (hnRNPs), whose levels and activities vary across cell
types. SR proteins generally contain one or two RNA recognition motifs (RRMs) and a domain rich in
alternating Arg and Ser residues (RS domain). Generally, RRM domains confer RNA binding specific-
ity while the RS domain mediates protein-protein and protein-RNA interactions to affect splicing
(Long and Caceres, 2009; Zhou and Fu, 2013). Post-translational modifications of SR proteins,
most notably phosphorylation, modulate their splicing regulatory capacity by altering protein locali-
zation, stability or activity (Gui et al., 1994; Lai et al., 2003; Prasad et al., 1999; Shin and Manley,
2002). Dynamic changes in SR protein phosphorylation have been detected after DNA damage
(Edmond et al., 2011; Leva et al., 2012) and during the cell cycle (Gui et al., 1994; Shin and Man-
ley, 2002), suggesting that regulation of AS may have important roles in cell cycle control. However,
the functional consequences of SR protein (de)phosphorylation during the cell cycle are largely
unclear.
Through a global-scale analysis of the human transcriptome at single-nucleotide resolution
through two continuous cell cycles, we have identified widespread periodic changes in AS that are
coordinated with specific stages of the cell cycle. These periodic AS events belong to a set of genes
that is largely separate from the set of genes periodically regulated during the cell cycle at the tran-
script level, yet the AS regulated set is significantly enriched in cell cycle- associated functions. We
further demonstrate that a significant fraction of the periodic AS events is regulated by the SR pro-
tein kinase, CLK1, and that CLK itself is also subject to cell cycle-dependent regulation. Moreover,
eLife digest Mitosis is a key step in the normal life cycle of a cell, during which one cell divides
into two new cells. As a cell progresses through the cell cycle, it must carefully regulate its gene
activity to switch particular genes on or off at specific moments. When a gene is activated its
sequence is first copied into a temporary molecule called a transcript. These transcripts are then
edited to form templates to build proteins. One way that a transcript can be edited is via a process
called alternative splicing, in which different pieces of the transcript are cut and pasted together to
form different versions of the final template. This allows different instructions to be obtained from a
single gene, introducing an added layer of biological complexity. However, the role of alternative
splicing in the timing of key events of the cell life cycle is not well understood.
Dominguez et al. have now looked for the genes that undergo alternative splicing during the cell
cycle. The sequences of gene transcripts produced within human cells were collected while the cells
went through two rounds of division. This approach revealed that around 1,300 genes are spliced in
different ways at different stages of each cell cycle. Many of these genes were known to play roles in
controlling the cell’s life cycle, but few of the genes showed large changes in the amount of total
transcript that is generated over time.
Dominguez et al. also showed that an enzyme called CLK1 influences about half of the 1,300
periodically spliced genes during the cell cycle. The production of CLK1 is itself carefully controlled
throughout the cell cycle, and the enzyme’s activity prevents its own overproduction. Further
experiments showed that blocking CLK1’s activity while a cell is replicating its DNA halts the cell
cycle, but blocking this enzyme’s activity after the cell had replicated its DNA did not. Given this
pivotal role in the cell cycle, Dominguez et al. also examined the role of CLK1 in cancer cells and
found that high levels of CLK1 in tumours were linked to lower survival rates. These findings indicate
that CLK1 warrants further investigation, particularly in relation to its role in cancer.
DOI: 10.7554/eLife.10288.002
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inhibition or depletion of CLK1 causes pleiotropic defects in mitosis that lead to cell death or G1/S
arrest, suggesting that the temporal regulation of splicing by CLK1 is critical for cell cycle progres-
sion. The discovery of periodic AS thus reveals a widespread yet previously underappreciated mech-
anism for the regulation of gene function during the cell cycle.
Results
Alternative splicing is coordinated with different cell cycle phases
To systematically investigate the regulation of AS during the cell cycle, we performed an RNA-Seq
analysis of synchronously dividing cells using a total of 2.3 billion reads generated across all stages
(G1, S, G2 and M) of two complete rounds of the cell cycle (Figure 1—figure supplement 1A). To
maximize the detection of regulated AS events, we used the complementary analysis pipelines,
MISO and VAST-TOOLS (Katz et al., 2010; Irimia et al., 2014). These pipelines have different
detection specificities and employ partially overlapping reference sets of annotated AS events, and
therefore afford a more comprehensive analysis when employed together. Both pipelines were used
to determine PSI (the percent of transcript with an exon spliced in) and PIR (the percent of tran-
scripts with an intron retained). Alternative exons detected by both pipelines had highly correlated
PSI values (Figure 1—figure supplement 1G; see below). Consistent with previous results (Bar-
Joseph et al., 2008; Whitfield et al., 2002), transcripts from approximately 14.2% (1182) of
expressed genes displayed periodic differences in steady-state levels between two or more cell cycle
stages (see below). Remarkably, 15.6% (1293) of expressed genes also contained 1747 periodically-
regulated AS events, among a total of ~ 40,000 detected splicing events (FDR < 2.5%; Figure 1A
and Figure 1—figure supplement 1B,D).
Importantly, as has been observed previously for AS regulatory networks (Pan et al., 2004), the
majority of genes with periodic AS events did not overlap those with periodic steady-state changes
in mRNA expression. This indicates that genes with periodic changes in AS and transcript levels are
largely independently regulated during the cell cycle (Figure 1B). Further supporting this conclusion,
we did not observe a significant correlation (positive or negative) between exon PSI values and
mRNA expression levels for genes with both periodic expression and periodic exon skipping (data
not shown). A gene ontology (GO) analysis reveals that genes with periodic AS, like those with peri-
odic transcript level changes (Bar-Joseph et al., 2008; Whitfield et al., 2002), are significantly
enriched in cell cycle-related functional categories, including M-phase, nuclear division and DNA
metabolic process (Figure 1C; adjusted p<0.05 for all listed categories, FDR<10%)
(Supplementary file 1). Similar GO enrichment results were observed when removing the relatively
small fraction (10%) of periodically spliced genes that also display significant mRNA expression
changes across the cell cycle (Figure 1C). These results thus reveal that numerous genes not previ-
ously linked to the cell cycle, as well as previously defined cell cycle-associated genes thought to be
constantly expressed across the cell cycle, are in fact subject to periodic regulation at the level of AS
(Supplementary file 1 for a full list).
Among the different classes of AS analyzed (cassette exons, alternative 5’/3’ splice sites and
intron retention [IR]), periodically regulated IR events were over-represented (relative to the back-
ground frequency of annotated IR events) by ~ 2.2 fold whereas periodically regulated cassette
exons, represent the next most frequent periodic class of AS (p=2.210-16, Fisher’s exact test, Fig-
ure 1—figure supplement 1E). Quantitative RT-PCR assays across different cell cycle stages vali-
dated periodic IR events detected by RNA-Seq (Figure 1D). Interestingly, one of these IR events is
in transcripts encoding aurora kinase B (AURKB), a critical mitotic factor regulated at the levels of
transcription, protein localization, phosphorylation and ubiquitination (Carmena et al., 2012;
Lens et al., 2010). The AURKB retained intron is predicted to introduce a premature termination
codon that elicits mRNA degradation through nonsense mediated decay, and is thus expected to
result in reduced levels of AURKB protein. The splicing of the retained intron lags behind changes in
the total AURKB mRNA expression (Figure 1E). We computationally corrected levels of fully spliced,
protein coding AURKB mRNA by taking into account the fraction of intron-retaining (i.e. non-produc-
tive) transcripts across the cell cycle stages (Figure 1E). The expression curve for corrected AURKB
mRNA levels is substantially different from total AURKB transcript levels, with a shifted peak coincid-
ing with mitosis. Periodically-regulated IR events detected in other genes, including those with
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known cell cycle functions such as HMG20B and RAD52, are similarly expected to affect the cell
cycle timing of mRNA expression (Figure 1A,D). Collectively, these results provide evidence that the
temporal control of retained intron AS provides an important mechanism for establishing the timing
of expression of AURKB mRNA and protein, as well as of the timing of expression of additional
genes during the cell cycle.
Figure 1. Global detection of periodic cell cycle-dependent alternative splicing. (A) Heat map representation of periodically spliced events. Row-
normalized relative PSI values are shown. Diagram below indicates cell cycle phase. (B) Overlap between periodically spliced genes and periodically
expressed genes detected by RNA-Seq. (C) Heat map representation of enriched Gene Ontology terms shown as log (p-value). Three gene sets were
analyzed separately: all genes with periodic AS, genes with periodic AS only, and genes with both periodic AS and periodic expression. (D) Real-time
quantitative PCR analysis of periodic retained introns and total mRNAs for three selected genes. Cells were synchronized by double thymidine block
and samples were collected 0, 3, 6, 9, 12 and 15 hr post release. Errors bars represent standard deviation of the mean. Diagram below indicates cell
cycle stage. (E) Schematic representation of AURKB AS pattern. Line graph showing the relationship between intron retention and mRNA levels for the
AURKB gene across the cell cycle. Percent intron retention (solid red line) across cell cycle was used to determine the fraction of total mRNAs (solid
blue line) not containing an intron, i.e. ‘corrected’ mRNA levels (dashed blue line).
DOI: 10.7554/eLife.10288.003
The following figure supplement is available for figure 1:
Figure supplement 1. Identification of periodic AS by multiple analysis pipelines.
DOI: 10.7554/eLife.10288.004
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The SR protein kinase CLK1 fluctuates during the cell cycle
Alternative splicing is generally regulated by the concerted action of multiple cis-elements that
recruit cognate splicing factors. Consistently, analysis of our RNA-seq data revealed 96 RNA binding
proteins (RBPs) with periodic mRNA expression, including RS domain-containing factors like SRSF2,
SRSF8, TRA2A and SRSF6 (Figure 2—figure supplement 1A). These 96 RBPs were significantly
enriched in the GO term ’splicing regulation’ (adjusted p=10-4, Figure 2—figure supplement 1B),
indicating that periodic AS is likely controlled by multiple RBPs. Correlations between these RBPs
and periodic splicing events were also identified (Figure 2—figure supplement 1C). For example,
SRSF2 expression is significantly correlated with the splicing pattern of a retained intron in the
SRSF2 transcript. Further supporting a role for these RBPs in controlling periodic splicing was the
identification of RNA motifs bound by a subset of periodically expressed RBPs (Figure 2—figure
supplement 1D). To further examine periodic RBP regulation during cell cycle, we measured the
abundance of known splicing regulatory proteins at different stages of the cell cycle by immunoblot-
ting (Figure 2A). Among the proteins analyzed, CDC-like kinase 1 (CLK1), an important regulator of
the Ser/Arg (SR) repeat family of splicing regulators, displayed the strongest cyclic expression
Figure 2. Cell cycle-dependent regulation of CLK1. (A) Immunoblot analysis of proteins involved in splicing regulation in synchronized HeLa cells after
release from double thymidine block. (B) Immunoblot analysis of selected proteins in asynchronous HeLa cells or cells arrested at different cell cycle
stages. Stably expressed exogenous CLK1 levels were also assessed during the cell cycle (bottom panel). (C) Immunoblot of endogenous CLK1 (top)
and exogenously-expressed wild type (CLK1wt) or kinase catalytically inactive (CLK1KD) proteins (bottom) upon treatment with 10 mM TG003. (D) Co-
expression of CLK1WT and CLK1KD at different ratios. (E) Immunoprecipitation of CLK1 proteins co-expressed with myc-ubiquitin. Cells were treated
with 10 mM TG003 and 10 mM MG132 prior to sample collection. (F) Immunoblot analysis of lysates from cells synchronized upon early S phase (double
thymidine) release with or without TG003 treatment.
DOI: 10.7554/eLife.10288.005
The following figure supplements are available for figure 2:
Figure supplement 1. Periodic expression of RBPs.
DOI: 10.7554/eLife.10288.006
Figure supplement 2. Regulation of CLK1 proteins levels during the cell cycle is degradation-dependent.
DOI: 10.7554/eLife.10288.007
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peaking at the G2/M phase (Figure 2A,B), consistent with the results of a recent mass-spectrome-
try-based screen for cycling proteins (Ly et al., 2014). CLK1 is one of four human CLK paralogs
(CLK1-4) and is known to regulate AS via altering the phosphorylation status of multiple SR proteins
(Duncan et al., 1997; Jiang et al., 2009; Ninomiya et al., 2011; Prasad et al., 1999). Notably, the
levels of other detectable CLK paralogs, as well as members of another SR protein kinase, SRPK1,
did not change significantly at the level of RNA and/or protein during the cell cycle (Figure 2B and
Supplementary file 1).
Given that both CLK1 protein levels and known CLK1 substrates are periodically expressed, we
decided to further investigate the role of CLK1 in the context of cell cycle. The levels of total CLK1
mRNA, as well as the levels of specific CLK1 splice variants, did not change significantly during the
cell cycle (Figure 2—figure supplement 2A,B) indicating that periodic expression of CLK1 is con-
trolled at the level of protein translation and/or turnover. Consistent with this, an exogenously
expressed CLK1 protein displayed cell cycle-dependent fluctuations similar to those observed for
endogenous CLK1 protein (Figure 2B). Moreover, CLK1 was rapidly degraded upon inhibition of
translation by cycloheximide, and this effect was reversed by co-treatment with the proteasome
inhibitor MG132 (Figure 2—figure supplement 2C). Additionally, polyubiquitination of Flag-tagged
CLK1 was detected following immunoprecipitation with anti-Flag antibody from cells treated with
MG132 (Figure 2—figure supplement 2D). These data suggest that the levels of CLK1 protein are
controlled by ubiquitin-mediated degradation in a cell cycle-dependent manner.
Periodically regulated protein levels are often controlled through negative feedback circuits
involving auto-regulatory loops. CLK1 has been reported to auto-phosphorylate on several residues
(Ben-David et al., 1991). To investigate whether auto-phosphorylation of CLK1 affects its periodic
regulation, we tested whether blocking its kinase activity affects its stability. Inhibition of CLK1
kinase activity using a selective inhibitor, TG003 (Muraki et al., 2004), markedly stabilizes both
endogenous and exogenously expressed CLK1 proteins (Figure 2C). Moreover, activity-dependent
destabilization of CLK1 was observed with a wild type (WT) protein, but not with a catalytically inac-
tive (KD) mutant (Figure 2C, left panel). We further observe that WT CLK1 is rapidly degraded upon
cycloheximide treatment, whereas the KD mutant is more stable (Figure 2—figure supplement 2C).
We next tested whether CLK1 activity is sufficient to trigger its own degradation by co-expressing
KD CLK1 with increasing amounts of WT CLK1. As expected, increasing amounts of WT CLK1
reduces levels of KD CLK1 (Figure 2D). Consistent with these results, WT CLK1 is more highly polyu-
biquitinated compared to the KD mutant (Figure 2E, compare lanes 2 to 4), and treatment with
TG003 reduces polyubiquitination levels (Figure 2E, lane 2 vs. 3 and lane 4 vs. 5). Decreased polyu-
biquitination of WT CLK1 is more prevalent than is apparent upon TG003 treatment, as CLK1 is sta-
bilized by TG003 inhibition and thus more total Flag-CLK1 is immunoprecipitated (Figure 2E). To
further examine whether this auto-feedback loop is required for changes in CLK1 protein levels dur-
ing the cell cycle, we treated synchronized cells with TG003 (or DMSO as a control) and measured
CLK1 protein levels. We observed that CLK1 inhibition prevents its turnover after the G2/M phase
for both endogenous and exogenously expressed kinases (Figure 2F and Figure 2—figure supple-
ment 2E). Taken together, these results provide strong evidence that CLK1 protein levels are con-
trolled by ubiquitin-mediated proteolysis in a cell cycle stage-specific manner, and that an activity-
dependent negative feedback loop is required for this periodic regulation. These results further sug-
gest that changes in the levels of CLK1 could account for many of the periodically regulated AS tran-
sitions we have detected during the cell cycle.
CLK1 regulates AS events in genes with critical roles in cell cycle
control
RNA-Seq analysis of cells treated with TG003 revealed 892 AS events (in 665 genes) that significantly
change after CLK1 inhibition (Figure 3A), including known CLK1-regulated splicing events (e.g. exon
4 of CLK1 [Duncan et al., 1997]). It is worth noting that TG003 can also inhibit CLK4 (although to a
lesser extent than inhibition of CLK1). However, RNAi of CLK1 is sufficient to recapitulate the pheno-
type of CLK1/4 inhibition (see below and Figure 4) (Fedorov et al., 2011; Muraki et al., 2004).
Intron retention and cassette exons are the most overrepresented types of AS affected by TG003
(Figure 3A). Most (70%) of the CLK1-regulated exons display increased skipping upon CLK1 inhibi-
tion, whereas 87% of CLK1-regulated introns show increased retention (Figure 3—figure supple-
ment 1B and C), consistent with a recently reported role for CLK1 in the regulation of retained
Dominguez et al. eLife 2016;5:e10288. DOI: 10.7554/eLife.10288 6 of 19
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Figure 3. CLK1 regulates a network of genes that control cell cycle progression. (A) Identification of endogenous CLK1 targets by RNA-Seq. Numbers
of different AS types affected by treatment with the CLK1 inhibitor TG003 (left graph). SE, skipped exon; RI, retained intron; A3E, alternative 3’ exon;
A5E, alternative 5’ exon. Fraction of total analyzed events that were affected by TG003 treatment (right graph). (B) Validation of TG003-responsive AS
events by semi-quantitative RT-PCR. The bar graph shows the max-delta PSI for each AS event tested in a 24-hr time course of inhibition with 20mM
TG003. (C) Representation of cell cycle control genes with CLK1-dependent AS events, organized by cell cycle phase and function. (D) Schematic
representation of CHEK2 alternative splicing, showing that exon 9 encodes a region overlapping the kinase domain (upper panel). Semi-quantitative
RT-PCR assessment of CHEK2 isoforms after treatment with TG003 or over-expression of the indicated factors (lower left panel). RNAi of SRSF1 in cells
and subsequent analysis of CHEK2 splicing by semi-quantitative RT-PCR (lower right panel). PSI values are shown below gel. (E) Normalized CENPE
total mRNA expression during an unperturbed cell cycle (triangle denotes mitosis, left panel) and diagram of CENPE splicing (right). TG003-treatment
Figure 3 continued on next page
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introns (Boutz et al., 2015). Of nine analyzed TG003-affected AS events detected by RNA-Seq anal-
ysis, all were validated by semi-quantitative RT-PCR assays (Figure 3B). These observations indicate
that CLK1 inhibition mainly suppresses splicing, consistent with a general requirement for phosphor-
ylation of SR proteins to promote splicing activity (Irimia et al., 2014; Prasad et al., 1999;
Tsai et al., 2015). Importantly, there is a significant overlap between genes with cell cycle periodic
AS events (Figure 1) and those with CLK1-regulated AS events, involving 156 genes (p=8.510-10,
hyper-geometric test). In contrast, consistent with the results in Figure 1, we do not observe a signif-
icant overlap between genes containing CLK1-regulated AS events and periodically expressed
genes. These results thus support a widespread and rapidly acting role for CLK1 in controlling cell
cycle-regulated AS. Indeed, CLK1 inhibition induces rapid (within 3–6 hr) changes in AS among sev-
eral analyzed cases (Figure 3—figure supplement 1D).
Supporting an important role for CLK1 in cell cycle progression, genes whose AS levels are
affected by CLK1 inhibition are significantly enriched in the GO terms cell cycle phase, M-phase,
DNA metabolic processes, nuclear division, DNA damage response, and cytokinesis (adjusted
p<0.05 and FDR <20% for all listed GO terms; full list in Supplementary file 2). The affected genes
function at various stages of cell cycle including the G1/S transition (Figure 3C). Mitotic processes
were, however, associated with the largest number of CLK1-target genes with AS changes and
included examples that function in centriole duplication (CEP70, CEP120, CEP290, CEP68,
CDK5RAP2), metaphase and anaphase (e.g. CENPK, CENPE, CENPN), and cytokinesis (e.g. SEPT2,
SEPT10, ANLN) (additional examples in Figure 3C).
To further investigate the functional consequence of CLK1-dependent AS, we selected two exam-
ples in genes that have important roles in the cell cycle: checkpoint kinase 2 (CHEK2), a tumor sup-
pressor that controls the cellular response to DNA damage and cell cycle entry (Paronetto et al.,
2011; Staalesen et al., 2004), and centromere-associated protein E (CENPE), a kinetochore-associ-
ated motor protein that functions in chromosome alignment and segregation during mitosis
(Kim et al., 2008). We detected a TG003 dose-dependent increase in CHEK2 exon 9 inclusion,
whereas overexpression of WT CLK1 induced exon 9 skipping, an event that removes the CHEK2
kinase domain (Figure 3D). Expression of WT CLK1 in the presence of TG003, or a catalytically inac-
tive CLK1, had little to no effect on the splicing of this exon (Figure 3D, bottom panels), indicating
that the catalytic activity of CLK1 is essential for regulating CHEK2 AS. Over-expression of the SR
protein splicing regulator SRSF1, a known target of CLK1 (Prasad et al., 1999), had a similar effect
as over-expression of CLK1, resulting in CHEK2 exon 9 skipping, whereas knockdown of SRSF1 had
the opposite effect (Figure 3D, right panel). Furthermore, the activation of CHEK2 requires homodi-
merization (Shen et al., 2004), and we observe that the CHEK2 isoform lacking exon 9 still interacts
with full-length protein (Figure 3—figure supplement 1E), suggesting that this CLK1-regulated iso-
form may function in a dominant-negative manner to attenuate CHEK2 activity.
CENPE is known to be tightly controlled at multiple levels (including transcription, localization,
phosphorylation and degradation), and disruption of its regulation leads to pronounced mitotic
defects. CENPE AS generates long and short isoforms (Supplementary file 2), with the predominant
variant being the short isoform that lacks amino acids 1972–2068. Inhibition of CLK1 rapidly shifts
CENPE splicing to produce predominantly the long isoform (Figure 3E), and this is accompanied by
a reduction in CENPE protein levels during G2/M phase, presumably due to the instability of the
long isoform (Figure 3E). These data thus show that CLK1 controls the AS of major cell cycle regula-
tors, and therefore suggest that inhibition of CLK1 may alter cell cycle progression.
To investigate this, we next performed an RNA-Seq analysis of synchronized cells at G1 and early
G2 (when CLK1 accumulates), following inhibition of CLK1 with TG003. As a specificity control, we
Figure 3 continued
of HeLa cells released from G1/S arrest followed by semi-quantitative RT-PCR analysis of CENPE isoforms (bar graph). (F) Schematic of RNA-Seq
analysis of CLK1 inhibition during cell cycle (left). AS events that were identified as being differentially regulated between G1 and G2 phase (top bar of
bar graph) and number of events that were blocked by the indicated conditions (bottom 4 bars).
DOI: 10.7554/eLife.10288.008
The following figure supplement is available for figure 3:
Figure supplement 1. CLK1 regulates a network of genes that control cell cycle progression.
DOI: 10.7554/eLife.10288.009
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Figure 4. CLK1 is required for cell cycle progression and proliferation. (A) Immunoblot analysis of CLK1 proteins
after stable shRNA knockdown in HeLa cells. Bottom, DNA content as measured by propidium iodide staining
following flow cytometry. (B) Immunofluorescence microscopy of A549 cells depleted of CLK1 by shRNA (top row),
cells treated with 10 mM TG003 for 12 hr (middle row), and a control treatment with DMSO (bottom row); green:
tubulin, red: emerin (nuclear envelope), and blue: DAPI. Scale bar 10 mm. Right bar graph shows the quantification
of multinucleated cells. p values determined using Student’s t-test. (C) Static frames from a live-cell high-content
imaging movie of HeLa cells expressing Histone H2B-GFP and treated with TG003 (top panel). Time after start of
Figure 4 continued on next page
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performed a parallel RNA-Seq analysis using a structurally distinct CLK1 inhibitor, KHCB-19
(Fedorov et al., 2011). Strikingly, of 1498 AS events that change between G1 (t=0) and G2 (t=6)
~ 94% display reduced changes following treatment with the two drugs (Figure 3F), with 65% com-
monly affected by both drugs, thus supporting an important role for CLK1 in controlling cell-cycle
dependent splicing.
CLK1 is required for normal mitosis and cell proliferation
Given that CLK1 regulates the AS of many cell cycle factors (Figure 3C), we next examined whether
it is necessary for cell cycle progression. Knockdown of CLK1 using shRNAs led to an accumulation
of cells with 4N DNA content in multiple cell types, specifically HeLa, H157, and A549 (Figure 4A,
Figure 4—figure supplement 1A,B), and the extent of this accumulation correlated with the degree
of knockdown (Figure 4—figure supplement 1A). We also observed a significant increase in multi-
nucleation, a common consequence of defective chromosome segregation or cytokinesis, following
shRNA-knockdown or TG003 inhibition of CLK1 in the treated cells (Figure 4B and Figure 4—figure
supplement 1C). To visualize the effect of CLK1 inhibition on mitosis at a single cell level, we per-
formed time-lapse high-content microscopy on live cells stably expressing a GFP-histone 2B fusion
protein, to track changes in chromatin. TG003-treated cells entered mitosis normally, as measured
Figure 4 continued
the experiment is indicated; EP, end point ( ~ 960 min). TG003 treated cells with apparent cell division defects
(indicated by arrowheads in the bottom field) are shown in two independent fields. (D) Synchronized HeLa cells
were treated with 20 mM TG003 at the indicated time points (0, 5, and 10 hr) and analyzed by propidium iodide
staining and flow cytometry to measure DNA content. Percent of 2N (lower bar graph) and 4N (upper bar graph)
cells were quantified at each time point as indicated in the treatment scheme (top). (E) Colony formation assay of
HeLa cells depleted of CLK1 by shRNA, or continuously treated with TG003 or KHCB-19 at the indicated
concentrations. (F) Box plot representation of CLK1 mRNA expression levels in paired normal and tumorous
kidney tissue. 72 cases were analyzed. (G) Kaplan-Meier plot showing survival differences between patients with
kidney tumors with high CLK1 (red, upper quartile) or reduced CLK1 (blue, lower three quartiles) expression. (H)
Number of cancer-associated AS events that are also regulated by CLK1 in different tumor types. BRCA, Breast
invasive carcinoma; COAD, Colorectal adenocarcinoma; KIRC, Kidney renal clear cell carcinoma; LUAD, Lung
adenocarcinoma; LUSC, Lung squamous cell carcinoma; LIHC, liver hepatocellular carcinoma.
DOI: 10.7554/eLife.10288.010
The following figure supplements are available for figure 4:
Figure supplement 1. Loss of CLK1 results in cell cycle defects in multiple cell types.
DOI: 10.7554/eLife.10288.011
Figure supplement 2. CLK1 mis-regulation in human cancer.
DOI: 10.7554/eLife.10288.012
Video 1. Live-cell imaging of control HeLa cells stably
expressing a GFP-H2B. Cells were synchronized by
single-thymidine block and released and imaged at
10X magnification (every ~ 15 min) for 960 min.
DOI: 10.7554/eLife.10288.013
Video 2. Live-cell imaging of control HeLa cells stably
expressing GFP-H2B. Cells were synchronized by
single-thymidine block and released into 1 mM of
TG003 and imaged at 10X magnification (every ~ 15
min) for 960 min.
DOI: 10.7554/eLife.10288.014
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by nuclear envelope breakdown, but displayed delayed or aberrant cytokinesis, typically resulting in
multi-polar divisions, increased time in metaphase, failure to undergo chromatin de-condensation
and eventual cell death (Figure 4C and Videos 1–5). To further determine at what cell cycle stage
CLK1 activity is required, we inhibited CLK1 using TG003 at different time points after early S phase
release. Consistent with the imaging data, both control and TG003-treated cells entered mitosis nor-
mally, as measured by 4N DNA content. However, inhibition of CLK1 before late S-phase impaired
progression through mitosis, whereas cells treated 5 hr after early S phase release underwent a
round of normal mitotic division, although failed to enter the next cell cycle (Figure 4D and Fig-
ure 4—figure supplement 1D). These results suggest that the primary defects caused by CLK1 inhi-
bition occur in late S-phase and G2 phase, which is when CLK1 levels normally begin to rise
(Figure 2A). This conclusion is further supported by the observation that CLK1-dependent AS tar-
gets, such as those detected in HMMR and CENPE, are periodically expressed during cell cycle and
peak during G2 and M phase (Figure 4—figure supplement 1E). Taken together with the earlier
results, these data support an important and multifaceted role for CLK1 in the control of cell cycle
progression through its function in the global regulation of periodic AS.
CLK1 expression and CLK1-regulated AS is altered in kidney cancer
The importance of CLK1 for faithful progression through the cell cycle suggests it may play a
role the control of cell proliferation in cancer. Supporting this, shRNA knockdown or chemical
inhibition of CLK1 with TG003 or KHCB-19 in HeLa cells results in a near complete block in cell
proliferation, as measured by anchorage-
dependent and -independent colony formation
assays (Figure 4E and Figure 4—figure sup-
plement 1F). As mentioned above, CLK1 is
likely the primary target of inhibition in these
experiments since RNAi of CLK1 recapitulates
the phenotype seen with these chemical
inhibitors.
Using RNA-Seq data from the Cancer
Genome Atlas (TCGA) (Cancer Genome Atlas
Network, 2013) we observe that CLK1 displays
significantly higher expression in 72 kidney
tumors compared to matched normal tissue
samples (Figure 4F, p=10-5, Kolmogorov-Smir-
nov test). Consistently, most CLK1-controlled AS
events that are altered in tumors have expected
splicing changes (Figure 4—figure supplement
2A). Furthermore, patients with tumors that
Video 3. Zoom of live-cell imaging of control HeLa
cells. Data associated with Figure 4D.
DOI: 10.7554/eLife.10288.015
Video 4. Zoom of live-cell imaging of TG003-treated
HeLa cells. Data associated with Figure 4.
DOI: 10.7554/eLife.10288.016
Video 5. Zoom of live-cell imaging of TG003-treated
HeLa cells. Data associated with Figure 4.
DOI: 10.7554/eLife.10288.017
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have elevated CLK1 expression (i.e. the upper quartile of all samples) have significantly lower survival
rates relative to other patients in the comparison group (Figure 4G, p=0.007). While there was also
an increase in CLK2, CLK3 and CLK4 mRNA expression in these tumors, CLK1 displayed the highest
relative mRNA expression levels compared to CLK2 and CLK3 (Figure 4—figure supplement 2B).
Levels of the CLK4, which is ~ 80% identical to CLK1, did not correlate with survival differences
despite its increased levels in tumors (Figure 4—figure supplement 2C). Consistent with this, CLK1-
regulated AS events, as defined by the RNA-Seq analysis in Figure 3, were also altered across multi-
ple tumor types, including breast, colon, lung and liver (Figure 4H and Figure 4—figure supple-
ment 2D). These data are further consistent with a multi-faceted role for CLK1 in regulating cell
cycle progression, and also suggest that CLK1 contributes to increased cell proliferation in cancer, at
least in part through its role in controlling periodic AS.
Discussion
Previous studies have shown that splicing and the cell cycle are intimately connected processes.
Indeed, cell cycle division (CDC) loci originally defined in S. cerevisiae, namely cdc5 and cdc40, were
subsequently shown to encode spliceosomal components (Ben-Yehuda et al., 2000;
McDonald et al., 1999). Moreover, genome-wide RNAi screens for new AS regulators of apoptosis
genes in human cells revealed that factors involved in cell-cycle control, in addition to RNA process-
ing components, were among the most significantly enriched hits (Moore et al., 2010;
Tejedor et al., 2015). An RNAi screen performed in Drosophila cells for genes required for cell-cycle
progression identified numerous splicing components (Bjo¨rklund et al., 2006) as well as a Drosoph-
ila ortholog of CLK kinases, Darkener of apricot Doa (Bettencourt-Dias et al., 2004). In other stud-
ies, negative control of splicing during M phase was shown to be dependent on dephosphorylation
of the SR family protein, SRSF10 (Shin and Manley, 2002), and the mitotic regulator aurora kinase A
(AURKA) was shown to control the AS regulatory activity of SRSF1 (Moore et al., 2010). Our study
shows for the first time that AS patterns are subject to extensive periodic regulation, in part via a
global control mechanism involving cell cycle fluctuations of the SR protein kinase CLK1. At least
one likely function of this periodic AS regulation is to control the timing of activation of AURKB (Fig-
ure 1), as well as of numerous other key cell cycle factors shown here to be subject to periodic AS.
The definition of an extensive, periodically-regulated AS program in the present study thus opens
the door to understanding the functions of an additional layer of regulation associated with cell cycle
control and cancer.
Since many RBPs are found to be periodically expressed (Figure 4A), it is likely that other aspects
of mRNA metabolism are also coordinated with cell cycle stages. For example, differential degrada-
tion could potentially contribute to the observed periodic fluctuation of splice isoforms during cell
cycle. The degradation of mRNA is closely linked with alternative polyadenylation, which has
emerged as a critical mechanism that controls mRNA translation and stability. Generally, shortened
3’ UTRs are found in rapidly dividing cells and more aggressive cancers (Mayr and Bartel, 2009).
This study identified 94 cases periodic alternative poly-A site usage (data not shown) in genes known
to regulate cell cycle and/or proliferation, including SON, CENPF and EPCAM (Ahn et al., 2011;
Bomont et al., 2005; Chaves-Perez et al., 2013). In addition, many mRNAs have recently been
found to be translated in a cell cycle dependent fashion (Aviner et al., 2015; Maslon et al., 2014;
Stumpf et al., 2013). Interestingly, a fraction of periodically translated genes are also periodically
spliced, including key regulators of cell cycle (e.g., AURKA, AURKB, TTBK1 and DICER1). This obser-
vation is consistent with recent findings that the regulation of AS and translation may be coupled
(Sterne-Weiler et al., 2013). In summary, we have demonstrated that AS is subject to extensive tem-
poral regulation during the cell cycle in a manner that appears to be highly integrated with orthogo-
nal layers of cell cycle control. These results thus provide a new perspective on cell cycle regulation
that should be taken into consideration when studying this fundamental biological process, both in
the context of normal physiology and diseases including cancers.
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Materials and methods
Cell culture and synchronizations
HeLa (a kind gift from J. Trejo), HEK 293T (from ATCC CRL-3216) and A549 (kind gift from W. Kim)
cells were maintained in DMEM (Gibco) medium supplemented with 10% FBS (Gibco). All cells were
cultured in humidified incubators with 5% CO2. Cell cycle synchronization was adapted from the pro-
tocol of Whitfield et al. (Whitfield et al., 2002); ~ 750,000 log phase HeLa cells were plated in 15
cm dishes in complete media and allowed to attach for 16 hr, reaching <30% confluence. Cells were
subsequently treated with 2 mM thymidine (Sigma-Aldrich, St. Louis, MO) for a total of 18 hr,
washed 2 times with 1xPBS, and supplemented with fresh complete media for 10 hr. 2 mM thymi-
dine was subsequently added for a second block of 18 hr and washed as described previously.
Mitotic block was performed by double thymidine arrest (as above) and release in fresh media for
3.5 hr followed by addition of nocodazole 100 mM (Sigma) for 10 hr. G1 block was performed by
serum starvation for 72 hr in DMEM containing 0.05% FBS. For RNA-Seq, cells (both adherent and
detached) were harvested every 1.5 hr for 30 hr and frozen immediately for purification of total
RNA. To block the activity of CLK1, cells were treated with TG003 (Sigma), KHCB-19
(Tocris, Bristol, UK). To block activity of the proteasome cells were treated with MG132 (Sigma).
Drugs were-suspended in DMSO and added to growing cultures at the indicated concentrations and
times.
Flow cytometry and cell cycle analysis
Cells were harvested with trypsin treatment, washed 2 times in cold 1xPBS and subsequently fixed in
80% ice cold ethanol for at least 4 hr. Cells were then washed twice with 1xPBS and suspended in
propidium iodide/RNase staining buffer (BD Pharmingen, cat # 550825). Cells were analyzed by flow
cytometry to count 10,000 cells that satisfied gating criteria. Data collected were analyzed using
ModFit software to discern 2N (G1), S-phase, and 4N (G2 and M) composition.
Mapping and filtering of RNA-Seq data
RNA-Seq reads were mapped to the human genome (build hg19) using the MapSplice informatics
tool with default parameters (Wang et al., 2010). The mapped reads were further analyzed with Cuf-
flinks to calculate the level of gene expression with FPKM (Fragments Per Kilobase per Million
mapped reads) (Trapnell et al., 2010). The levels of alternatively spliced isoforms were quantified
with MISO (Mixture-of-Isoforms) probabilistic framework (Katz et al., 2010) using the annotated AS
events for human hg19version 2. The levels of alternatively spliced isoforms were also quantified
with VAST-TOOLS using the event annotation as previously described (Irimia et al., 2014). Each AS
event was assigned a PSI or PIR value to represent the percent of transcripts with the exon spliced
in, or the intron retained, respectively.
Identification of periodic AS
For identification of periodic AS raw PSI/PIR values were normalized as:
normalized F s
n
  
¼
F s
n
 F s
min
F s
max
where s = 1 to 32,109 for all splicing events; n = 1 to 14 for the 14 samples; F min is the minimum
and F max is the maximum PSI value among the 14 samples.
To identify periodic AS events, normalized gene expression values (normalized FPKM values as
en) for the well-known periodic gene, CCNB1, CCNA2, CCNB2, and CENPE, were used as a starting
point to subsequently add curves with broader or sharper peaks as well as shifted to left or right,
resulting in 7 periodic expression curves that cover all the phases of cell cycle (Figure 1—figure sup-
plement 1A). We term these ’ideal seed curves’, which capture intermittent peak times and phase
shifts that were not well represented within the initial known periodic genes. To identify genes with
similar splicing patterns across the cell cycle, we computed the EuclideanDistanceED of each AS event
s to the model seed curves m as follows:
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EDm;s ¼
X14
n¼1
jnormalizedðem
n
Þ  normalizedð F s
n
Þj
where m = 1 to 7 for all model seed curves, s = 1 to 32,109 for all AS events.
Based on the ranking of distance, a similar cutoff of ED  2:75 was set as a minimum requirement
for periodic AS. Lastly, we calculated a false discovery rate (FDR) by shuffling PSI values across the
14 time points 10,000 times and calculating how often a random shuffle had a better periodic score
than the true periodic score for that event. A maximum FDR of 2.5% was required for a splicing
event to be periodic.
Heat maps, correlations, GO-term analysis, overlap analysis and
statistics
Heat maps, hierarchical clustering, and Pearson correlations were generated using GENE-E (www.
broadinstitute.org/cancer/software/GENE-E/). All heat maps shown are row-normalized for presenta-
tion purposes. Spearman’s rank correlation with average linkage was used for clustering. DAVID
(http://david.abcc.ncifcrf.gov/gene2gene.jsp) was used for all gene ontology enrichment; terms
shown are for biological process (GOTERM_BP_FAT). To test for significance in overlap analysis,
overlapping genes in two data sets (i.e. TG003-treatment and periodic AS) and a background set of
only co-detected events was used (i.e. genes detected in both experiments). Significance of overlap-
ping gene sets was assessed using the hyper-geometric test. For overlap and correlation analysis
between VAST-TOOLS and MISO we used two MISO AS event annotations (HG18 and HG19), due
to differences in the input annotation files for these two pipelines. To identify the 4,343 overlapping
exons in the heatmap, we used MISO hg19v1 annotations and MISO hg18 annotations, and the
VAST-TOOLS annotations. Student’s t-test was used to measure significant in cell cycle defects
(multi-nucleation and flow-cytometry) as well as semi-quantitative RT-PCR assessment of splice var-
iants. To identify AS events blocked by TG003 or KHCB19, a Student’s t-test statistic was used. If a
change between G1/S (t=0) and G2 (t=6) was significant, but not significant in the presence of inhibi-
tors we consider that event to be blocked. For over-representation of periodic introns, we per-
formed Fisher’s exact test in a 2x2 contingency table as compared to skipped exons. For differences
in expression of CLK1 mRNAs in kidney cancers a Kolmogorov-Smirnov test was performed. For sur-
vival differences, the survdiff function in the R survival package was used (as discussed in methods
below).
Plasmid construction, transfections and RNAi
The expression constructs were generated by cloning the cDNA of CLK1 into pCDNA3 (for transient
expression) or pCDH (for stable transfection) backbones with different epitope tags (HA or Flag) at
the N- or C-terminus. The Myc-His-Ubiquitin expression vector is a gift from Dr. Gary Johnson’s lab,
and the Histone H2B-GFP expression vector is gift from Dr. Angelique Whitehurst’s lab. Plasmid
transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. The lentiviral vectors of shRNAs were obtained from Addgene in pLKO.1 TRC cloning plas-
mid through UNC core facility as part of mammalian gene knockdown consortium. Lentiviral infec-
tions were performed according to the manufacturer’s instruction from System Biosciences (SBI).
Semi-quantitative RT-PCR assays for monitoring splicing
Cells transfected with shRNA constructs or treated with TG003 were lysed and total RNA was
extracted using the Trizol method (Life Technologies). Purified RNA was treated with 1U of RNAse-
free DNAase (Promega) for 1 hr at 37˚C and reverse transcribed using random hexamer cDNA prep-
aration kit (Applied Biosystem). One-tenth of the RT product was used as the template for PCR
amplification (25 cycles of amplification, with a trace amount of Cy5-dCTP in addition to non-fluores-
cent dNTPs) using gene specific primers listed in Supplementary file 4. The resulting gels were
scanned with a Typhoon 8600 Imager (GE Healthcare), and analyzed with ImageQuant 5.2 software
(Molecular Dynamics/GE Healthcare). Real time PCR was carried out using the SYBR Green kit (Invi-
trogen) and GAPDH as an internal control.
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Immunoblotting and immunoprecipitation
Proteins were extracted in lysis buffer (CHAPS 1% w/v, 150 mM NaCl, 50 mM MgCl2 with protease
inhibitor), resolved by SDS-PAGE and transferred onto PVDF membrane. For immunoprecipitaion
experiments to detect ubiquitination, cells were co-transfected with Flag-CLK1 and myc-ubiquitin
constructs as above. 36 hr later, TG003 (20 mM) was added for 18 hr. 4 hr prior to harvesting, 10 mM
of MG132 was added to the media. Proteins were extracted in lysis buffer as above with the addition
of NEM. Incubation with EZ-View FLAG Beads (Sigma) was performed for 2 hr at 4˚C. Samples were
extensively washed according to the manufacturer’s protocol and subjected to immunoblotting.
Antibodies and dilutions are listed in Supplementary file 4.
Immunofluorescence and high-content live-cell imaging
For immunofluorescence microscopy, cells were plated on glass coverslips coated with poly-L-Lysine.
Cells were then washed twice with 1xPBS, fixed with 4% formaldehyde (Sigma), permeabilized with
0.05% Triton X-100 (Promega) and blocked with 3% BSA (Fisher); all dilutions were made in 1XPBS.
For live cell imaging, HeLa cells transduced with Histone H2B-GFP was stably selected as described
previously (Cappell et al., 2010). Cells were plated in a 6-well format and treated with 2 mM thymi-
dine for 24 hr, subsequently washed and released in fresh complete medium with or without TG003
(20 mM). Cells were imaged using the BD Pathway Microscope with a 10X objective.
Colony formation assays
HeLa cells stably producing shRNAs targeting CLK1 or control shRNAs were plated at low density
(1000 cells/6 cm2) in standard culture medium and allowed to proliferate for 9 days. Cells were then
fixed and stained with crystal violet at room temperature. The dried plates were used for estimations
of colony diameter and number.
Kidney cancer analysis of CLK1 and alternative splicing
RNA-Seq data from the The Cancer Genome Atlas (Ciriello et al., 2013) was processed as previ-
ously described (Tsai et al., 2015). Briefly, for mRNA expression, RSEM expression values for the
indicated genes were analyzed in 79 paired KIRC (tumor and normal) samples and the paired ks-test
was used to test significance. For alternative splicing analysis data from BRCA: Breast invasive carci-
noma, COAD: Colorectal adenocarcinoma, KIRC: Kidney renal clear cell carcinoma, LUAD: Lung ade-
nocarcinoma, LUSC: Lung squamous cell carcinoma, LIHC: liver hepatocellular carcinoma were
analyzed through the MISO pipeline as described above (Tsai et al., 2015). Relapse-free survival
was analyzed using Kaplan Meier plots. All plots and statistical analyses (survdiff) were generated
using the R package version 3.1.1 survival function.
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